Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough

Japanese pharma Shionogi is looking to build on the success of its GSK- and Pfizer-partnered infectious disease joint venture ViiV Healthcare as it pens a new licensing deal for a long-acting HIV asset.